Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT-302 + Eylea vs Eylea in neovascular AMD
2024-512880-30-00Phase 3Completed
- Sponsor
- Opthea Limited
- Start
- Aug 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial of sozinibercept in exudative macular degeneration (2 arms), sponsored by Opthea Limited. Primary endpoint: Mean change from baseline to Week 52 in ETDRS best-corrected visual acuity (BCVA) letters. Started Aug 2024; status: completed.
02
Drugs
sozinibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2024-512880-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512880-30-00.